Company: RGBP
Filing Date: 2025-05-28
Form Type: 10-Q
Source: 0001641172-25-012619
Chunk: 20

Company: Regen BioPharma Inc
Filing Date: 2025-05-28
Form: 10-Q
Item: Part I, Item 2
Chunk 20
---
Item
2. MANAGEMENT’ S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

CERTAIN
FORWARD-LOOKING INFORMATION

Information
provided in this Quarterly report on Form 10Q may contain forward-looking statements within the meaning of Section 21E or Securities
Exchange Act of 1934 that are not historical facts and information. These statements represent the Company’s expectations or beliefs,
including, but not limited to, statements concerning future and operating results, statements concerning industry performance, the Company’s
operations, economic performance, financial conditions, margins and growth in sales of the Company’s products, capital expenditures,
financing needs, as well assumptions related to the forgoing. For this purpose, any statements contained in this Quarterly Report that
are not statement of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based on current
expectations and involve various risks and uncertainties that could cause actual results and outcomes for future periods to differ materially
from any forward-looking statement or views expressed herein. The Company’s financial performance and the forward-looking statements
contained herein are further qualified by other risks including those set forth from time to time in the documents filed by the Company
with the Securities and Exchange Commission. All references to” We”, “ Us”, “ Company” or the “ Company”
refer to Regen BioPharma, Inc.

Results
of Operations

Three
months and six months ended March 31, 2025 and 2024

Revenues

Revenues
from continuing operations were $59,065 for the three months ended March 31, 2025 and $59,064 for the same period ended 2024. $27,425
of revenue from related parties recognized during the three months ended March 31 2025 and consisted of anniversary expense receivable
pursuant to a license granted by the Company to Zander Therapeutics, Inc. as did $27,425 for the period ended 2024. $31,640 of revenue
recognized during both of the three months ended March 31, 2025 and 2024 were recognized pursuant to licenses granted to Oncology Pharma,
Inc.

Revenues
from continuing operations were $118,130 for the six months ended March 31, 2025 and $118,129 for the same period ended 2024. $54,850
and $54,849 of revenue from related parties recognized during the six months ended March 31 2025 and